Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 12:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 146 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Skin Red Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

High Fluence Light Emitting Diode-Red Light (LED-RL) in Human Skin

NCT02630303
View directory record Official record
Conditions
Fibrosis, Scarring, Scar, Wounds, Injuries, Keloid, Cicatrix, Hypertrophic
Interventions
LED-RL Phototherapy, Mock Therapy
Device
Lead sponsor
Jared Jagdeo, MD, MS
Federal
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Mather, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Jul 23, 2026, 12:19 PM EDT
Completed No phase listed Observational

Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)

NCT05074719
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19, Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome)
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
10 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Jul 23, 2026, 12:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Melanin Index in Those With Fitzpatrick Skin Phototypes I-VI

NCT01124513
View directory record Official record
Conditions
Erythema
Interventions
Induced Erythema
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Jul 23, 2026, 12:19 PM EDT
Recruiting Not applicable Interventional

Efficacy of Red Kinesiology Tape on Carpal Tunnel-Like Symptoms and Performance in Esports Gamers

NCT06757062
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Kinesiology Tape
Device
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 2, 2025 · Synced Jul 23, 2026, 12:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Influence of Mango Intake of Skin Health in Postmenopausal Women

NCT03590756
View directory record Official record
Conditions
Wrinkle, Skin Red
Interventions
16 weeks mango intake
Other
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2019 · Synced Jul 23, 2026, 12:19 PM EDT
Completed Phase 1 Interventional

CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes

NCT04508205
View directory record Official record
Conditions
Rosacea
Interventions
CGB-400
Drug
Lead sponsor
CAGE Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Fremont, California • San Diego, California • Edgewater, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Jul 23, 2026, 12:19 PM EDT
Completed Early Phase 1 Interventional

Non-invasive Fluorescent Imaging System for Imaging Mohs Tumor

NCT03430934
View directory record Official record
Conditions
Skin Cancer
Interventions
NAVI mapping with Indocyanine green
Combination Product
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Jul 23, 2026, 12:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Civamide Patch Safety, Tolerability and PK Study

NCT00758433
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Zucapsaicin, Placebo patch
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Port Chester, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Jul 23, 2026, 12:19 PM EDT
Recruiting No phase listed Observational

Familial Investigations of Childhood Cancer Predisposition

NCT03050268
View directory record Official record
Conditions
Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2037
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 12:19 PM EDT
Completed Phase 2 Interventional

Dose Response Study of Patients With Erythematous Rosacea

NCT01186068
View directory record Official record
Conditions
Erythematous (Type One) Rosacea
Interventions
V-101, vehicle
Drug · Other
Lead sponsor
Vicept Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
7
States / cities
San Diego, California • Miami Beach, Florida • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2010 · Synced Jul 23, 2026, 12:19 PM EDT
Completed No phase listed Observational

Pyruvate Kinase Deficiency Natural History Study

NCT02053480
View directory record Official record
Conditions
Pyruvate Kinase Deficiency, Congenital Non-Spherocytic Hemolytic Anemia
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
19
States / cities
Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Jul 23, 2026, 12:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Single-Center, Clinical Study to Evaluate the Safety of a Fragranced Personal Lubricant in Healthy Female Subjects

NCT02320214
View directory record Official record
Conditions
Erythema, Edema
Interventions
Miami w/ frag Personal lubricant
Device
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Jul 23, 2026, 12:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pulsed Dye Laser (PDL) vs. Microsecond 1064-nm Nd:YAG Laser for Treatment of Diffuse Facial Redness

NCT01529996
View directory record Official record
Conditions
Rosacea
Interventions
Pulse Dye Laser/YAG laser
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Jul 23, 2026, 12:19 PM EDT
Completed Phase 3 Interventional Results available

Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

NCT01318733
View directory record Official record
Conditions
Rosacea
Interventions
CD07805/47 gel 0.5%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
27
States / cities
Santa Monica, California • Denver, Colorado • Longmont, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 23, 2026, 12:19 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor

NCT01000662
View directory record Official record
Conditions
Breast Cancer
Interventions
Daily Radiation Therapy, Weekly Radiation Therapy
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Jul 23, 2026, 12:19 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Validation of a New Hand Held Light Emitting Diode Device for the Determination of Minimal Erythema Dose (MED)

NCT01818154
View directory record Official record
Conditions
Phototherapy
Interventions
LED phototherapy, narrowband UVB phototherapy
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Jul 23, 2026, 12:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Human Repeat Insult Patch Test to Evaluate Personal Lubricants

NCT02737631
View directory record Official record
Conditions
Erythema, Edema
Interventions
"Chameleon" Personal Lubricant
Device
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
222 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Jul 23, 2026, 12:19 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Comparison of Two Modes of Photodynamic Therapy for the Treatment of Actinic Keratosis on the Upper Extremities

NCT05359419
View directory record Official record
Conditions
Skin Neoplasms
Interventions
aminolevulinic acid hydrochloride gel, 10%, aminolevulinic acid HCl topical solution, 20%
Combination Product
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
35 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Jul 23, 2026, 12:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema

NCT01933464
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Cromolyn Sodium, Normal Saline
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Jul 23, 2026, 12:19 PM EDT
Terminated Phase 1 Interventional Results available

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

NCT02231710
View directory record Official record
Conditions
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies, Metabolic Disorders
Interventions
BPX-501 and Rimiducid
Biological
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
4 Months to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Jul 23, 2026, 12:19 PM EDT
Completed Phase 3 Interventional Results available

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

NCT01636687
View directory record Official record
Conditions
Plaque-type Psoriasis
Interventions
Placebo, Secukinumab 150mg, Secukinumab 300mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Jul 23, 2026, 12:19 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Cancer in Inherited Bone Marrow Failure Syndromes

NCT00027274
View directory record Official record
Conditions
Diamond Blackfan Anemia, Dyskeratosis Congenita, Fanconi Anemia, Shwachman Diamond Syndrome, Inherited Bone Marrow Failure Syndrome, Aplastic Anemia
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Day to 100 Years
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
2
States / cities
Bethesda, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 12:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"

NCT03954444
View directory record Official record
Conditions
Rosacea
Interventions
Oxymetazoline Hydrochloride, Rhofade Cream, 1%, Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Jul 23, 2026, 12:19 PM EDT
Active, not recruiting Phase 2 Interventional

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

NCT02876107
View directory record Official record
Conditions
Breast Carcinoma, Breast Lump, Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative, Inflammatory Breast Carcinoma, Invasive Breast Carcinoma, Peau d'Orange, Progesterone Receptor Negative, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Panitumumab
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 23, 2026, 12:19 PM EDT